Marco Investment Management LLC continued to hold its stake in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,350 shares of the biopharmaceutical company’s stock at the end of the first quarter. Marco Investment Management LLC’s holdings in Keryx Biopharmaceuticals were worth $279,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the stock. Norges Bank purchased a new position in shares of Keryx Biopharmaceuticals during the fourth quarter valued at approximately $9,973,000. Deerfield Management Co. bought a new stake in shares of Keryx Biopharmaceuticals during the fourth quarter valued at about $7,568,000. Iridian Asset Management LLC CT acquired a new stake in shares of Keryx Biopharmaceuticals during the fourth quarter valued at $1,339,000. Knoll Capital Management LP acquired a new stake in shares of Keryx Biopharmaceuticals during the third quarter valued at $1,030,000. Finally, Old West Investment Management LLC increased its stake in shares of Keryx Biopharmaceuticals by 53.9% in the fourth quarter. Old West Investment Management LLC now owns 209,629 shares of the biopharmaceutical company’s stock valued at $1,228,000 after buying an additional 73,405 shares during the last quarter. Hedge funds and other institutional investors own 62.26% of the company’s stock.
Keryx Biopharmaceuticals, Inc. (NASDAQ KERX) traded up 1.16% on Tuesday, hitting $6.08. The stock had a trading volume of 564,962 shares. The firm’s market capitalization is $659.47 million. The company’s 50 day moving average is $6.38 and its 200-day moving average is $5.81. Keryx Biopharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $7.80.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by $0.03. Keryx Biopharmaceuticals had a negative net margin of 387.12% and a negative return on equity of 1,122.28%. The company had revenue of $11.82 million for the quarter, compared to the consensus estimate of $10.19 million. During the same period in the prior year, the company earned ($0.39) earnings per share. The firm’s revenue was up 73.2% on a year-over-year basis. On average, analysts forecast that Keryx Biopharmaceuticals, Inc. will post ($0.69) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.thestockobserver.com/2017/06/20/marco-investment-management-llc-has-279000-stake-in-keryx-biopharmaceuticals-kerx-updated-updated.html.
A number of analysts have recently commented on KERX shares. Maxim Group reissued a “buy” rating and issued a $7.00 price objective on shares of Keryx Biopharmaceuticals in a research note on Friday, March 3rd. ValuEngine cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Cowen and Company reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a report on Saturday. One analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. Keryx Biopharmaceuticals has a consensus rating of “Hold” and an average price target of $8.16.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.